A TWELVE-MONTH, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF EVEROLIMUS WITH BASILIXIMAB, CORTICOSTEROIDS AND TWO DIFFERENT EXPOSURE LEVELS OF TACROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS: